Vaccine
AssigneesID Biomedical Corporation of Quebec, The Council of the Queensland Institute of Medical Research
InventorsGeorge H Lowell, George L White, Michael R Batzloff, David S Burt, Tomas B Leanderson, Michael F Good
Life of this patent
Estimating the term…
Abstract
Effective stimulation of immune responses is achieved through the use of a group A streptococcal antigen combined with proteosome adjuvant. The compositions are provided in particular for intranasal administration. The vaccine compositions are provided for use in inducing an immune response in an individual for the treatment or prophylaxis of group A streptococcal infection in an individual, preferably via prevention or reduction of colonisation of the throat following intranasal administration.
Claims13
A vaccine composition comprising a proteosome adjuvant and a group A Streptococcal antigen that comprises an antigenic peptide between 15 and 30 amino acids in length from the conserved C-terminal region of an S. pyogenes M protein, wherein the antigenic peptide comprises the amino acid sequence ASREAKKQVEKALE (SEQ ID NO:1), and wherein the antigen is attached to a hydrophobic moiety.
Dependencies are inferred from the claim text.